Dive into the archives.
- Don’t Hold Your Breath For Generic Avonex
September 16, 2009 — 11:47am ET | By George Miller
Biogen Idec has succeeded in extending patent protection for its multiple sclerosis drug Avonex to 2026, some 13 years beyond the original patent-expiration date. The IP sleight of hand comes in the form of a newly issued method-of-use patent, which also covers Avonex treatment of multiple [...]
- Biogen Reports 2 More Cases of PML with Tysabri
By THOMAS GRYTA
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan PLC, the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since [...]
- Avonex Pre-Filled Syringes and My Wretched Side Effects
Sometimes interferons, including AVONEX, make people feel sad. If you are taking AVONEX, and feel unusually sad, you should tell a family member or friend right away and call your healthcare provider as soon as possible.
Some people have had severe allergic reactions, a drop in their red or white blood cell levels, a drop in [...]
- Elan and Biogen are in a Fight
Elan starts legal action in drug row with Biogen
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging [...]
- 11th Case of PML Reported With Tysabri
The 11the patient on Tysabri has developed a potentially deadly brain infection.
This is what happened when three people who were on Tysabri and other medications for Multiple Sclerosis had previously contracted the brain infection and two died, according to InjuryBoard.com which tracks such drug reactions. Then, the drug was taken off the market briefly.
Biogen Idec, [...]
- Tired of Patients vs. Profits? Quit Throwing Fuel on the Fire
By Trista Morrison | July 9th, 2009
Is anyone else tired of hearing that drug companies care more about profits than patients? Me, too. But even more tiresome than the anti-pharma rhetoric is the fact that industry keeps pouring fuel on the fire.
True, most drug makers got into the business in order to help [...]
- Biogen Receives FDA Fast Track Status for PEGylated Interferon Beta-1a
July 8, 2009
Biogen Idec (NASDAQ: BIIB) today announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon [...]
- First 10-Year Follow-Up Shows That AVONEX® Leads To Long-Term Benefits In Early MS Pts
July 4, 2009
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who [...]
- Hot off the AAN Press: Tysabri Promotes Remyelination
July 4, 2009
Biogen Idec (NASDAQ: BIIB) and Elan Corporation (NYSE: ELN) announced results of a study demonstrating that Tysabri® (natalizumab) promoted regeneration and stabilization of damage done to the myelin sheath, as measured by advanced MRI technology. Damage to the myelin sheath causes the symptoms of multiple sclerosis (MS). Additional posters were presented during the [...]
- Biogen Reports 13th Case of PML
By KEITH J. WINSTEIN
Biogen Idec Inc.’s disclosure of a debilitating brain infection in a patient taking its Tysabri multiple-sclerosis medicine sparked a selloff in shares of the biotechnology company Monday.
The disclosure, made Friday evening, marks the 13th case of the infection, called progressive multifocal leukoencephalopathy or PML, in a Tysabri patient. Three of the patients [...]
